JP2014513727A - Ｃｘｃｒ４拮抗薬の使用 - Google Patents

Ｃｘｃｒ４拮抗薬の使用 Download PDF

Info

Publication number
JP2014513727A
JP2014513727A JP2014511460A JP2014511460A JP2014513727A JP 2014513727 A JP2014513727 A JP 2014513727A JP 2014511460 A JP2014511460 A JP 2014511460A JP 2014511460 A JP2014511460 A JP 2014511460A JP 2014513727 A JP2014513727 A JP 2014513727A
Authority
JP
Japan
Prior art keywords
methylene
bis
phenylenebis
tetraazacyclotetradecane
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014511460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513727A5 (enExample
Inventor
デイヴィッド・シー・デイル
ゲイリー・ジェイ・ブリジャー
フランク・ジェイ・シュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2014513727A publication Critical patent/JP2014513727A/ja
Publication of JP2014513727A5 publication Critical patent/JP2014513727A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014511460A 2011-05-16 2012-05-15 Ｃｘｃｒ４拮抗薬の使用 Withdrawn JP2014513727A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486632P 2011-05-16 2011-05-16
US61/486,632 2011-05-16
PCT/US2012/037970 WO2012158707A1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017017227A Division JP2017105809A (ja) 2011-05-16 2017-02-02 Ｃｘｃｒ４拮抗薬の使用

Publications (2)

Publication Number Publication Date
JP2014513727A true JP2014513727A (ja) 2014-06-05
JP2014513727A5 JP2014513727A5 (enExample) 2015-07-02

Family

ID=81755014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511460A Withdrawn JP2014513727A (ja) 2011-05-16 2012-05-15 Ｃｘｃｒ４拮抗薬の使用

Country Status (11)

Country Link
US (2) US20150030561A1 (enExample)
EP (1) EP2709991B1 (enExample)
JP (1) JP2014513727A (enExample)
KR (3) KR20140045411A (enExample)
CN (1) CN103596935A (enExample)
BR (1) BR112013029482A2 (enExample)
ES (1) ES2831049T3 (enExample)
MX (1) MX365242B (enExample)
PL (1) PL2709991T3 (enExample)
RU (1) RU2638802C2 (enExample)
WO (1) WO2012158707A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538337A (ja) * 2015-12-22 2018-12-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
JP2019533434A (ja) * 2016-09-08 2019-11-21 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ファンコニ貧血患者に対する遺伝子療法
JP2023547261A (ja) * 2020-10-20 2023-11-09 イーオーエム ファーマシューティカルズ インコーポレイテッド Ｃｏｖｉｄ－１９の処置のためのｅｏｍ６１３

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3058959T3 (pl) 2005-05-02 2019-07-31 Genzyme Corporation Terapia genowa dla zaburzeń neurometabolicznych
US9419667B2 (en) 2013-04-16 2016-08-16 Skyworks Solutions, Inc. Apparatus and methods related to conformal coating implemented with surface mount devices
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
CN113662937B (zh) * 2021-10-09 2022-08-23 江苏省人民医院（南京医科大学第一附属医院） Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途
CN116675708A (zh) * 2023-04-23 2023-09-01 华南师范大学 一类氧化响应的大环化合物、大环配合物及其应用
WO2025122961A1 (en) * 2023-12-08 2025-06-12 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088398A1 (en) * 2009-01-30 2010-08-05 Genzyme Corporation Methods and compositions for treating hematological malignancies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics, Inc. Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
CN100335478C (zh) 1999-12-17 2007-09-05 阿诺麦德股份有限公司 结合趋化因子受体的杂环化合物
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20070160574A1 (en) 2000-04-12 2007-07-12 Ahmed Merzouk Design of CXC chemokine analogs for the treatment of human diseases
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP1290033B1 (en) 2000-06-05 2012-10-31 The Trustees of Columbia University in the City of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
EP1322626B1 (en) 2000-09-29 2008-11-05 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
US20040157818A1 (en) 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
EP2371361B1 (en) 2001-07-31 2019-08-07 Genzyme Corporation Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1541585B1 (en) 2002-08-27 2013-01-30 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
JP3949708B2 (ja) 2003-04-02 2007-07-25 タイゲン・バイオテクノロジー ケモカイン受容体介在疾患を治療するためのポリアミン化合物
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
WO2006020891A2 (en) 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006095542A1 (ja) 2005-03-04 2006-09-14 Kureha Corporation アミン系化合物を含む医薬組成物
WO2007022385A2 (en) * 2005-08-18 2007-02-22 Novartis Ag Use of cxcr4 binding molecules for the treatment of whim syndrome
CN101365336B (zh) 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
JP2009527552A (ja) 2006-02-24 2009-07-30 ジェンザイム・コーポレーション 血流の増加および組織再生の促進またはそのいずれかのための方法
US8080659B2 (en) 2006-07-11 2011-12-20 Emory University CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders
AR063470A1 (es) 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
AR062271A1 (es) 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
JP5140686B2 (ja) 2007-02-28 2013-02-06 ポリファー リミテッド テンプレート固定ペプチド模倣薬
KR101210774B1 (ko) 2008-06-23 2012-12-10 리서치 인 모션 리미티드 디바이스 및 서버 능력을 전달하는 방법
WO2010025416A1 (en) 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088398A1 (en) * 2009-01-30 2010-08-05 Genzyme Corporation Methods and compositions for treating hematological malignancies
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6016007626; Ｂｌｏｏｄ．　２００５，　Ｖｏｌ．１０５，　Ｎｏ．６，　ｐ．２４４９-２４５７ *
JPN6016007630; Ｄｉｓ．　Ｍａｒｋｅｒｓ，　２０１０，　Ｖｏｌ．２９，　Ｎｏ．３-４，　ｐ．１８９-１９８ *
JPN6016007632; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　１９９９，　ｐ．３１０７６-３１０８６． *
JPN6016007636; Ｂｌｏｏｄ，　２００３，　Ｖｏｌ．１０２，　Ｎｏ．８，　ｐ．２７２８-２７３０ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538337A (ja) * 2015-12-22 2018-12-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
JP2021181501A (ja) * 2015-12-22 2021-11-25 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
JP7454255B2 (ja) 2015-12-22 2024-03-22 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
JP2019533434A (ja) * 2016-09-08 2019-11-21 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ファンコニ貧血患者に対する遺伝子療法
JP2022160505A (ja) * 2016-09-08 2022-10-19 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ファンコニ貧血患者に対する遺伝子療法
JP7197466B2 (ja) 2016-09-08 2022-12-27 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ファンコニ貧血患者に対する遺伝子療法
JP2023547261A (ja) * 2020-10-20 2023-11-09 イーオーエム ファーマシューティカルズ インコーポレイテッド Ｃｏｖｉｄ－１９の処置のためのｅｏｍ６１３

Also Published As

Publication number Publication date
EP2709991A4 (en) 2014-10-01
KR20210094672A (ko) 2021-07-29
RU2013155601A (ru) 2015-06-27
US20150030561A1 (en) 2015-01-29
MX2013013308A (es) 2014-02-27
ES2831049T3 (es) 2021-06-07
MX365242B (es) 2019-05-28
US20210161859A1 (en) 2021-06-03
KR20140045411A (ko) 2014-04-16
WO2012158707A1 (en) 2012-11-22
KR20200016407A (ko) 2020-02-14
BR112013029482A2 (pt) 2016-08-09
EP2709991A1 (en) 2014-03-26
RU2638802C2 (ru) 2017-12-15
CN103596935A (zh) 2014-02-19
PL2709991T3 (pl) 2021-04-06
EP2709991B1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
US20210161859A1 (en) Use of cxcr4 antagonists
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP2013231086A (ja) 化学療法の強化方法
TWI741286B (zh) 治療癌症之方法
US11628172B2 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20080234294A1 (en) Cxcr4 Binding Molecules
JP2017523178A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
US20110281814A1 (en) Methods and compositions for treating breast cancer
KR102505218B1 (ko) BCL-2 억제제와 MCl-1 억제제의 조합물, 이의 용도 및 약학적 조성물
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
JP2017105809A (ja) Ｃｘｃｒ４拮抗薬の使用
RU2780320C2 (ru) Применение антагонистов cxcr4
WO2014083095A1 (en) Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression
AU672288B2 (en) Rejection inhibitor for transplants and IL-1 production inhibitor
TWI846676B (zh) 用於治療胰腺癌的治療組合物
US11406605B2 (en) Therapeutic compositions for treating pancreatic cancer
WO2020232214A1 (en) Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
JP2020176145A (ja) 血液癌の併用療法
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
HK40007956A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161004

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170206